Asklepios BioPharmaceutical, Inc. (AskBio)

72 articles about Asklepios BioPharmaceutical, Inc. (AskBio)

• 

  AskBio Snags $235 Million Investment to Drive Gene Therapy Development

  4/11/2019

  The investment, which includes $225 million from Vida Ventures and TPG, as well as $10 million from AskBio’s founders and board members, is earmarked to advance and expand clinical trials.
• 

  Novartis’ AveXis to Build Gene Therapy Factory in Durham, North Carolina

  5/24/2018

  AveXis, a Novartis company based in Illinois, is investing $55 million to build a new manufacturing facility in Durham, North Carolina.
• 

  Asklepios BioPharma Launches New Biotech Actus Therapeutics

  12/15/2017

  Asklepios BioPharma is forming a new biotech portfolio company, Actus Therapeutics.

• Asklepios Looks for 6-Figure Incentive Package to Create 150 New Jobs

  10/9/2017

• Asklepios BioPharmaceutical, Inc. Enters Into License Agreement With Calimmune

  1/12/2016

• Asklepios BioPharmaceutical, Inc. And AveXis Finalize License

  6/17/2015

• Asklepios BioPharmaceutical, Inc. Executes License With Benitec Limited

  4/16/2015

• Asklepios BioPharmaceutical, Inc. Enters Cross-License Agreement With Genzyme Corporation

  7/16/2013

• REGENX Biosciences, LLC and Asklepios BioPharmaceutical, Inc. Enter Into Agreement for the Development of Treatments for Hemophilia A Using NAV(TM) rAAV8 Vectors

  3/8/2012

• Asklepios BioPharmaceutical, Inc. Enters Into A Patent License Agreement With Pfizer Inc.

  9/13/2010

• Asklepios BioPharmaceutical, Inc.: Non-Profit Founded to Advance Orphan Drug Research

  9/25/2007

• Asklepios BioPharmaceutical, Inc.. Announces Cross License With GlaxoSmithKline

  9/28/2006